Samsung Biologics Achieves 'Negligible Risk' Rating in Sustainalytics ESG Assessment
Earns ESG Risk Rating score of 9.0, ranking among the top 0.5% in the pharmaceuticals industry Advances from 'Low Risk' to 'Negligible Risk,' the lowest ESG risk category Recognition reflects continued improvements in ESG risk management across operations INCHEON, South Korea, Nov. 3,...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 100 stories mentioning NOV, the earliest published 26 Oct 2026.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.